BRPI0922483A2 - agonista de receptor gpr120 e usos dos mesmos - Google Patents

agonista de receptor gpr120 e usos dos mesmos

Info

Publication number
BRPI0922483A2
BRPI0922483A2 BRPI0922483A BRPI0922483A BRPI0922483A2 BR PI0922483 A2 BRPI0922483 A2 BR PI0922483A2 BR PI0922483 A BRPI0922483 A BR PI0922483A BR PI0922483 A BRPI0922483 A BR PI0922483A BR PI0922483 A2 BRPI0922483 A2 BR PI0922483A2
Authority
BR
Brazil
Prior art keywords
receptor agonist
gpr120 receptor
gpr120
agonist
receptor
Prior art date
Application number
BRPI0922483A
Other languages
English (en)
Inventor
Aaron Novack
Christopher J Rabbat
Dong Fang Shi
Imad Nashashibi
Jiangao Song
Jingyuan Ma
Phuongly Pham
Xin Chen
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41818563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922483(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of BRPI0922483A2 publication Critical patent/BRPI0922483A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Secondary Cells (AREA)
BRPI0922483A 2008-12-18 2009-12-17 agonista de receptor gpr120 e usos dos mesmos BRPI0922483A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13892308P 2008-12-18 2008-12-18
PCT/US2009/068576 WO2010080537A1 (en) 2008-12-18 2009-12-17 Gpr120 receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0922483A2 true BRPI0922483A2 (pt) 2015-12-15

Family

ID=41818563

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922483A BRPI0922483A2 (pt) 2008-12-18 2009-12-17 agonista de receptor gpr120 e usos dos mesmos

Country Status (26)

Country Link
US (3) US8309600B2 (pt)
EP (2) EP2514745A1 (pt)
JP (1) JP5746975B2 (pt)
KR (1) KR20110096071A (pt)
CN (2) CN103980235A (pt)
AR (1) AR074760A1 (pt)
AU (1) AU2009335797A1 (pt)
BR (1) BRPI0922483A2 (pt)
CA (1) CA2746762A1 (pt)
CL (1) CL2011001497A1 (pt)
CO (1) CO6400136A2 (pt)
CR (1) CR20110344A (pt)
DK (1) DK2367793T3 (pt)
EA (1) EA021515B1 (pt)
EC (1) ECSP11011149A (pt)
ES (1) ES2416980T3 (pt)
IL (1) IL213569A0 (pt)
MX (1) MX2011006574A (pt)
NI (1) NI201100126A (pt)
NZ (2) NZ593906A (pt)
SG (2) SG196838A1 (pt)
SV (1) SV2011003954A (pt)
TW (1) TW201028389A (pt)
UA (1) UA105779C2 (pt)
WO (1) WO2010080537A1 (pt)
ZA (1) ZA201104570B (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010008831A2 (en) * 2008-06-24 2010-01-21 Irm Llc Compounds and methods for modulating g protein-coupled receptors
EA022417B1 (ru) * 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
ES2526124T3 (es) * 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
WO2012035743A1 (ja) 2010-09-14 2012-03-22 パナソニック株式会社 レーダ装置
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US9801957B2 (en) 2011-04-06 2017-10-31 Ananth Annapragada Lipid-based nanoparticles
EP2758041B1 (de) 2011-09-20 2021-01-13 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung
EP2803664B1 (en) 2012-01-12 2018-11-21 Jiangsu Hengrui Medicine Co. Ltd. Tetrahydrobenzofurane derivatives as gpr40 agonists for the treatment of diabetes
EP2756459B1 (en) 2012-01-20 2020-12-09 Ananth Annapragada Methods and compositions for objectively characterizing medical images
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
CN105073111A (zh) * 2012-10-11 2015-11-18 默沙东公司 用作gpr120激动剂的取代的螺哌啶基化合物
KR101942752B1 (ko) 2012-11-05 2019-01-28 주식회사 엘지화학 Gpr120 효능제로서의 티오아릴 유도체
TWI692469B (zh) * 2012-11-09 2020-05-01 南韓商Lg化學股份有限公司 Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
KR102422559B1 (ko) 2013-03-14 2022-07-18 얀센 파마슈티카 엔.브이. Gpr120의 작용제로서 유용한 벤조 융합된 헤테로사이클릭 유도체
JP6333355B2 (ja) 2013-03-14 2018-05-30 ヤンセン ファーマシューティカ エヌ.ベー. Gpr120のアゴニストとして有用な二環式ピロール誘導体
WO2014159054A1 (en) 2013-03-14 2014-10-02 Janssen Pharmaceutica Nv Gpr120 agonists for the treatment of type ii diabetes
CN104109115B (zh) * 2013-04-16 2016-11-23 中国科学院上海药物研究所 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
PT3013796T (pt) 2013-06-27 2020-03-26 Lg Chemical Ltd Derivados biarílicos como agonistas de gpr120
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
CA2935897C (en) 2014-02-19 2018-07-03 Piramal Enterprises Limited Compounds for use as gpr120 agonists
US9067898B1 (en) 2014-03-07 2015-06-30 Janssen Pharmaceutica Nv Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
EP3114123B1 (en) * 2014-03-07 2018-04-25 Janssen Pharmaceutica NV Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes
US8912227B1 (en) 2014-03-07 2014-12-16 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of GPR120
WO2015168269A1 (en) 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
SG11201608299TA (en) 2014-05-01 2016-11-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
CA2955919A1 (en) 2014-07-25 2016-01-28 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
EP3191463B1 (en) 2014-09-11 2019-10-30 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
EP3542828A1 (en) 2014-10-08 2019-09-25 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
CA2974060C (en) 2015-02-05 2022-08-30 Piramal Enterprises Limited Compounds containing carbon-carbon linker as gpr120 agonists
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
CR20180229A (es) 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
CN107176944B (zh) * 2016-03-11 2020-05-01 中国科学院上海药物研究所 一种噻吩羧酸类化合物或其衍生物、其药物组合物、制备方法和用途
SG11201809559UA (en) 2016-06-13 2018-12-28 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
WO2018049328A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Bicyclic compounds useful as gpr120 modulators
KR102537985B1 (ko) 2016-09-12 2023-05-30 인테그랄 헬스 인코퍼레이티드 Gpr120 조정제로서 유용한 단환형 화합물
CN111285914B (zh) * 2018-12-10 2023-02-17 江西青峰药业有限公司 一种奥贝胆酸的制备方法
CN109694332A (zh) * 2018-12-27 2019-04-30 四川大学 一种苄胺衍生物烯基化的方法
CN110746450A (zh) * 2019-09-17 2020-02-04 济南康和医药科技有限公司 一种贝前列素钠关键中间体的合成方法
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
CN114163426B (zh) * 2020-09-10 2024-03-19 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用
CN112608378B (zh) * 2020-12-09 2023-09-08 江苏师范大学 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
MX2023007793A (es) 2020-12-30 2023-09-22 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas.
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
WO2022182954A1 (en) * 2021-02-26 2022-09-01 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treating type 2 diabetes using granulocyte-macrophage colony-stimulating factor (gm-csf)
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1437781A (en) * 1972-04-04 1976-06-03 Beecham Group Ltd Pyridine derivatives having hypoglycaemic activity
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4888353A (en) 1986-02-28 1989-12-19 Erbamont, Inc. Carboxamides useful as antiemetic or antipsychotic agents
US4705554A (en) * 1985-12-03 1987-11-10 Mitsubishi Chemical Industries Limited Benzofuranyloxyphenylurea derivative and herbicidal composition containing it as an active ingredient
US5032577A (en) * 1986-12-31 1991-07-16 Abbott Laboratories Peptidylaminodiols
DE3872937T2 (de) * 1987-05-11 1993-01-21 Ono Pharmaceutical Co Benzoylaminophenoxybuttersaeure-derivate.
US4959092A (en) * 1987-06-03 1990-09-25 Mitsubishi Kasei Corporation Substituted phenyl (or pyridyl) urea compound and herbicidal composition containing the same as active ingredient
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
JP2000501411A (ja) * 1995-12-05 2000-02-08 ダーウィン・ディスカバリー・リミテッド ベンゾフランカルボキサミドおよびスルホンアミド
ES2188983T4 (es) * 1996-08-19 2004-06-01 Altana Pharma Ag Nuevas benzofuran-4-carboxamidas.
DE19648793A1 (de) * 1996-11-26 1998-05-28 Basf Ag Neue Benzamide und deren Anwendung
AU8750298A (en) * 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US6921767B2 (en) * 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
WO2003099793A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
AU2003254781A1 (en) 2002-07-31 2004-02-16 Nippon Soda Co., Ltd. Aminosalicylamide derivative, process for producing the same and agri-horticultural pesticide
AR041481A1 (es) 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
CN1735408A (zh) * 2002-11-08 2006-02-15 武田药品工业株式会社 受体机能调节剂
JP2006516254A (ja) * 2003-01-06 2006-06-29 イーライ・リリー・アンド・カンパニー Pparモジュレータとしての縮合ヘテロ環誘導体
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
WO2005009104A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated Benzoic and phenyl acetic acid derivatives as hnf-4 modulators
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
US8008525B2 (en) * 2003-11-26 2011-08-30 Takeda Pharmaceutical Company Limited Receptor function regulating agent
WO2005066136A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Bicyclic derivatives as ppar modulators
CA2555814A1 (en) 2004-02-18 2005-09-01 Metabolex, Inc. Alpha-(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JPWO2006057448A1 (ja) 2004-11-26 2008-06-05 武田薬品工業株式会社 アリールアルカン酸誘導体
CA2591399C (en) * 2004-12-13 2014-05-20 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
US8288438B2 (en) 2005-03-21 2012-10-16 Metabolex, Inc. Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer
WO2007008963A1 (en) * 2005-07-13 2007-01-18 Jenrin Discovery Mao-b inhibitors useful for treating obesity
JP5071374B2 (ja) * 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ3阻害剤
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
WO2007070796A1 (en) * 2005-12-15 2007-06-21 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
AU2007225208A1 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
EP2061760A1 (en) * 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
AU2007314405A1 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2008054674A2 (en) * 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
TW200838526A (en) * 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
KR20090113901A (ko) 2007-02-22 2009-11-02 아이알엠 엘엘씨 G 단백질-커플링된 수용체를 조절하기 위한 화합물 및 방법
KR20090113382A (ko) 2007-02-22 2009-10-30 아이알엠 엘엘씨 G 단백질-커플링된 수용체의 조절제로서의 티아졸 유도체
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
EP2151236A4 (en) 2007-04-26 2013-01-16 Japan Science & Tech Agency G-PROTEIN-CONJUGATED RECEPTOR AGONIST
WO2008151211A1 (en) * 2007-06-05 2008-12-11 Sanofi-Aventis Substituted benzoylamino-indan-2-carboxylic acids and related compounds
WO2009046371A1 (en) 2007-10-05 2009-04-09 Metabolex, Inc. Methods of treating metabolic diseases
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルgpr40調節因子
JP5632612B2 (ja) * 2007-12-05 2014-11-26 あすか製薬株式会社 ラクタム化合物又はその塩及びppar活性化剤
CA2725316A1 (en) 2008-06-02 2009-12-10 Banyu Pharmaceutical Co., Ltd. Novel isoxazole derivative
EA022417B1 (ru) * 2008-10-21 2015-12-30 Саймабэй Терапевтикс, Инк. Арильные агонисты рецептора gpr120 и их применение
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.

Also Published As

Publication number Publication date
JP2012512893A (ja) 2012-06-07
EP2367793A1 (en) 2011-09-28
AU2009335797A1 (en) 2011-07-14
CN103980235A (zh) 2014-08-13
US20100190831A1 (en) 2010-07-29
US8598374B2 (en) 2013-12-03
NI201100126A (es) 2012-03-15
AR074760A1 (es) 2011-02-09
KR20110096071A (ko) 2011-08-26
EP2367793B8 (en) 2014-03-05
UA105779C2 (uk) 2014-06-25
ECSP11011149A (es) 2011-08-31
TW201028389A (en) 2010-08-01
MX2011006574A (es) 2011-08-03
NZ593906A (en) 2013-07-26
EA021515B1 (ru) 2015-07-30
CL2011001497A1 (es) 2011-09-30
SG196838A1 (en) 2014-02-13
CR20110344A (es) 2011-09-22
ES2416980T3 (es) 2013-08-05
IL213569A0 (en) 2011-07-31
EP2514745A1 (en) 2012-10-24
US20140121246A1 (en) 2014-05-01
DK2367793T3 (da) 2013-07-01
EA201190053A1 (ru) 2012-02-28
EP2367793B1 (en) 2013-03-27
HK1162023A1 (en) 2012-08-17
SV2011003954A (es) 2011-12-06
SG172125A1 (en) 2011-07-28
JP5746975B2 (ja) 2015-07-08
ZA201104570B (en) 2012-09-26
NZ611429A (en) 2014-12-24
WO2010080537A1 (en) 2010-07-15
CN102307860B (zh) 2014-07-02
CA2746762A1 (en) 2010-07-15
US20130131351A1 (en) 2013-05-23
CN102307860A (zh) 2012-01-04
US8309600B2 (en) 2012-11-13
CO6400136A2 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI0918868A2 (pt) moduladores do receptor de nmda e usos dos mesmos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0914682A2 (pt) compostos de heteroarila e usos dos mesmos
BRPI0914891A2 (pt) agonistas de aril gpr119 e usos dos mesmos
BRPI0920237A2 (pt) agonistas do receptor aril gpr120 e suas respectivas utilizações
BRPI0919539A2 (pt) antagonistas de receptor de opioide periférico e empregos dos mesmos
DE602008001416D1 (de) Sondenvorrichtung
BR112012015873A2 (pt) antagonistas de receptores ccr2 e usos dos mesmos
DK2313111T3 (da) Toll-lignende receptoragonistformuleringer og anvendelse deraf
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI0913656A2 (pt) anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos
EP2244636A4 (en) ADJUSTABLE SCANNER
BRPI0920209A2 (pt) conjugados de agonistas de glp-1 e usos dos mesmos
BRPI0922691A2 (pt) conjugados de leptina e análogo de leptina e usos dos mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BR112012003661A2 (pt) "compostos de biarila e métodos de uso dos mesmos."
BRPI0921230A2 (pt) agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.
EP2341905A4 (en) FORMULATIONS WITH NON-AQUEOUS SUPPORTS AND DELAYED FRUIT
BRPI0915675A2 (pt) Aparelho de medição
BRPI0909644A2 (pt) dispositivo de foto-epilação
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
BRPI1013943A2 (pt) Composto cetais e usos dos mesmos.
BRPI0817269A2 (pt) Análogos de azacitidina e usos dos mesmos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: CYMABAY THERAPEUTICS, INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]